Published March 13 & 20 (EPO); March 7 & 14 (WO)
Amrad Operations Variant WO 96/07737
Kew, Australia hematopoietin receptors
Hematopoietin receptors, component parts, and variants withencoding genes; for agonist assays.
Austin Res. Inst. Increased protein WO 96/06937
Heidelberg, Australia production
Method for increasing protein production in host cells by loweringthe amount of A and/or T rich exon regions.
Behringwerke Vascular gene WO 96/06938
Marburg, Germany therapy
Cell cycle-regulated activation of smooth muscle cell-specificpromoter-based vector; for vascular gene therapy.
Behringwerke Neural gene WO 96/06939
Marburg, Germany therapy
Cell cycle-regulated activation of glial cell-specific promoter-basedvector; for neural gene therapy.
Behringwerke Endothelial cell WO 96/06940
Marburg, Germany gene therapy
Cell cycle-regulated activation of endothelial cell-specific promoter-based vector; for endothelial cell gene therapy.
Behringwerke Immune system WO 96/06941
Marburg, Germany gene therapy
Cell cycle-regulated activation of immune system cell-specificpromoter-based vector; for immune system gene therapy.
Biotest Cytomegalovirus EPO 702 083
Dreleich, Germany fusion proteins
Polypeptides and fusion proteins with C-terminal fragments ofcytomegalovirus proteins, encoding genes (in German).
Biovector Therapeutics Immunogenicity WO 96/06638
Antigen immunogenicity enhancement by associating the antigenwith a phospholipid covered vector.
Boehringer Mannheim Retroviral WO 96/07747
Mannheim, Germany vector hybrids
Replication defective retroviral vector hybrids; for gene transfer inhematopoietic stem cells.
Children's Hosp. CNS regeneration WO 96/06859
Trophic factors for central nervous system (CNS) regeneration thatwere identified by culturing retinal nerve cells.
Chiron High yield IGF WO 96/07744
High yields of insulin-like growth factor (IGF) obtained by alkalinelysis of cell cultures.
Chiron Viagene Competent virus WO 96/07749
Emeryville, Calif. inhibition
Replication competent virus production inhibition by intracellularrecombination of vector genes causing cell death.
Dundee, Univ. of Apoptotic opioid WO 96/06863
Dundee, U.K. precursors
Products of opioid precursor molecule genes that are used as inducersor repressors of apoptosis.
Genentech Calcium phosphate WO 96/07750
S. San Francisco transfection
Calcium phosphate transfection method for eukaryotic cells in whichparticles are grown to optimal size.
Genvec Adenovirus penton WO 96/07734
Rockville, Md. vector
Recombinant adenovirus with gene for chimeric penton base andtherapeutic protein; for gene therapy.
German Hlth. & Targeted retroviral WO 96/07748
Welfare Res. Ctr. vectors
Non self-inactivating expression targeted retroviral vectors; for use intargeted gene therapy.
Hagiwara, Y. Anti-cancer idiotype EPO 702 082
Hyogo, Japan antibodies
Anti-idiotypic antibodies against anti-cancer human monoclonalantibodies, encoding gene; for cancer treatment.
Hoechst Mersacidin EPO 700 998
Frankfurt, Germany antibiotic
Gene for the peptide antibiotic mersacidin, encoded protein; fortreating infections.
Fred Hutchinson Rapid T cell WO 96/06929
Cancer Res. Ctr. expansion
Rapid expansion method for growing T cells using a non-dividingfeeder cell layer; for adoptive immunotherapy.
Igen Antibodies catalyzing EPO 701 818
Rockville, Md. peptide cleavage
Catalytic antibodies that cleave or form peptide linkages; for proteindegrading therapeutics.
Immtech Intl. C-reactive protein WO 96/06624
Evanston, Ill. muteins
Mutated C-reactive protein with one amino acid removed, encodinggene; for reducing aggregation.
Immutran Modified WO 96/07738
London complement proteins
Complement pathway proteins, such as C3, modified to form a stableC3 convertase, encoding genes, conjugates.
Japan Clin. Labs IGF-1 antibodies EPO 700 994
Monoclonal antibodies specific for insulin-like growth factor (IGF)-1; for assay kit.
Japan Poliomyelitis Poliovirus EPO 701 127
Res. Inst. vaccine neurotoxicity
Poliovirus vaccine neurotoxicity tested by inoculation into spinalchord of transgenic animal with poliovirus receptors.
La Jolla Cancer Res. Fdn. Adenoviral WO 96/07322
La Jolla, Calif. tumor sensitization
Sensitization of tumor cells by introduction of genes for adenovirusE1A polypeptides; for therapy.
Eli Lilly CDR-grafted WO 96/06625
Complementarity determining region (CDR)-grafted antibodieswhose binding/secretion are enhanced by molecular modeling.
Max Planck Inst. Genetically-altered WO 96/06942
Genetically-altered mature T-cells having an introduced gene andautoreactive receptors.
Merck Transgenic WO 96/06927
Rahway, N.J. Alzheimer's model
Transgenic mice with a gene encoding human amyloid precursorprotein gene; for evaluating Alzheimer's therapeutics.
Montreal, Univ. of Chimeric HIV WO 96/07741
Chimeric HIV Vpr and Vpx proteins that can be targeted to HIVgenomes; for treating infections.
Neurocrine Biosciences IL-1 type WO 96/07739
San Diego 3 receptors
Genes coding for soluble and membrane-bound forms of interleukin(IL)-1 type 3 receptors.
New England Biolabs Thermostable EPO 701 000
Beverly, Mass. DNA polymerase
Extremely thermostable DNA polymerase made by mutagenizing 3'-5' exonucleases, encoding gene.
New England Hematopoietic WO 96/06928
Deaconess Hosp. stem cells
Quiescent pluripotent hematopoietic stem cells substantially freefrom mature cells, isolation methods.
New York Blood Ctr. Yeast WO 96/07728
New York fibrinogen production
Production and secretion of recombinant fibrinogen and variants in ayeast host cell system.
New York Univ. Transfection WO 96/07731
New York complex
Complex of nucleic acids with polylysine and hypericin; fortransfection of mammalian cells.
Northern Illinois Univ. Ribozymes EPO 700 996
RNA catalyst with hairpin and substrate-binding segments, genecoding for this enzyme, expression vector.
Novo Nordisk Trefoil peptide WO 96/06861
Bagsvaerd, Denmark dimers
Trefoil peptide domains that are combined to form dimerizedmolecules.
Pasteur Inst. Rhesus protein WO 96/07740
DNA fragments coding for light and heavy chain domains ofmonoclonal antibodies to rhesus monkey proteins.
Pasteur Inst. Mycobacterial WO 96/07745
Paris screening vector
Mycobacterial expression vectors with reporter gene that can be usedto screen for infection.
Prizm Pharma VEGF-toxin WO 95/06641
San Diego conjugates
Vascular endothelial growth factor (VEGF) conjugated to toxins; fortargeted therapy of the endothelium.
Prolifix Cell cycle-regulated WO 96/06943
Cell cycle-regulated repressor that binds to a DNA element in controlsequences of cell cycle-regulated genes.
Roslin Inst. Cow embryonic WO 96/07732
Roslin, U.K. stem cells
Totipotent embryonic stem cells from cows and sheep; for in vitrocultivation and nuclear transfer to transgenics.
Sandoz Thrombomodulin WO 96/06933
Basel, Switzerland reducing inflammation
Cells expressing introduced gene for thrombomodulin; for reducingsusceptibility to inflammation.
Smit, V. Signal protein WO 96/06860
Delft, Netherlands modification
Signal protein modification using protease, chemical, and molecularbiological treatments; for increased activity.
Somatogenetics Intl. Hemoglobin EPO 700 997
Broomfield, Colo. production
Production of hemoglobin in a biologically active, secreted form inyeast or bacteria.
Tanuma, S. Chromatin DNA WO 96/07735
DNase that selectively cuts the linker site of chromatin DNA,encoding gene, antibodies; for viral therapy.
Viagene Therapeutic EPO 702 084
San Diego retroviral vectors
Recombinant retroviruses with vectors expressing proteins that treatinfectious, cancerous, and autoimmune diseases.
Yuka Medias Thymosin 1 EPO 700 993
Ibaraki, Japan antibodies
Hybridoma producing anti-thymosin 1 antibodies that recognize theN-terminal region; for assay kit.
Zymogenetics Immortalized WO 96/07733
Seattle precursor cells
Immortalized precursor cells prepared from growth suppressor gene-deficient animals; for screening assays.
_ Compiled By Chester A. Bisbee
(c) 1997 American Health Consultants. All rights reserved.